NCT06365970View on ClinicalTrials.gov

Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 31, 2025

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2028

Conditions
MMR-D/MSI-H Colorectal Cancers
Interventions
DRUG

Niraparib

An anti-cancer medication that helps to repair DNA when it becomes damaged, known as a PARP inhibitor.

DRUG

Dostarlimab

An anti-cancer medication that is a programmed death receptor-1 -blocking monoclonal antibody.

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Ibrahim Halil Sahin

OTHER